SILO
Silo Pharma Inc
$
0.667
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.7043
Open
0.6499
VWAP
0.66
Vol
765.09K
Mkt Cap
6.27M
Low
0.6183
Amount
502.43K
EV/EBITDA(TTM)
--
Total Shares
3.69M
EV
-144.54K
EV/OCF(TTM)
--
P/S(TTM)
44.15
Silo Pharma, Inc. is a developmental stage biopharmaceutical company. It is focused on developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It is engaged in acquiring and/or developing intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological disorders. Its lead program, SPC-15, is an intranasal treatment targeting post-traumatic stress disorder and stress-induced anxiety disorders. Its SP-26 is a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. Its two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis.
Show More
Valuation Metrics
The current forward P/E ratio for Silo Pharma Inc (SILO.O) is -0.94, compared to its 5-year average forward P/E of -1.18. For a more detailed relative valuation and DCF analysis to assess Silo Pharma Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-1.18
Current PE
-0.94
Overvalued PE
0.04
Undervalued PE
-2.41
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Overvalued
5Y Average PS
41.91
Current PS
92.21
Overvalued PS
83.66
Undervalued PS
0.16
Financials
Annual
Quarterly
FY2025Q2
YoY :
0.00%
18.03K
Total Revenue
FY2025Q2
YoY :
+24.51%
-1.25M
Operating Profit
FY2025Q2
YoY :
+29.25%
-1.20M
Net Income after Tax
FY2025Q2
YoY :
-38.71%
-0.19
EPS - Diluted
FY2025Q2
YoY :
+75.63%
-1.29M
Free Cash Flow
FY2025Q2
YoY :
0.00%
91.91
Gross Profit Margin - %
FY2025Q2
YoY :
+46.11%
-7.20K
FCF Margin - %
FY2025Q2
YoY :
+29.25%
-6.68K
Net Margin - %
FY2025Q2
N/A
ROIC
Trading Trends
Insider
Insiders areBuying! The selling amount has increased 106.44% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
1
4.3K
USD
Months
6-9
1
2.1K
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areBuying! The selling amount has increased 106.44% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
1
4.3K
USD
Months
6-9
1
2.1K
USD
Months
0-12
0
0.0
USD
Months
SILO News & Events
Events Timeline
2025-08-19 (ET)
2025-08-19
08:13:30
Silo Pharma Reveals Findings from 7-Day Safety Study of SPC-15 in Large Animals
2025-08-05 (ET)
2025-08-05
08:46:21
Silo Pharma appoints Corwin Yu to launch crypto treasury platform
2025-07-16 (ET)
2025-07-16
08:48:10
Silo Pharma completes dosing in safety study of SPC-15
Sign Up For More Events
Sign Up For More Events
News
9.0
08-21NewsfilterPinnedSilo Pharma's Alzheimer's Treatment SPC-14 Highlighted in Prestigious Scientific Journal
9.0
08-19NewsfilterPinnedSilo Pharma's SPC-15 for PTSD Reaches Key Safety Milestone, Clearing Path for Faster Clinical Trials via 505(b)(2) Pathway
9.0
07-16NewsfilterSilo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15
Sign Up For More News
People Also Watch
FAQ
What is Silo Pharma Inc (SILO) stock price today?
The current price of SILO is 0.6674 USD — it has increased 2.61 % in the last trading day.
What is Silo Pharma Inc (SILO)'s business?
What is the price predicton of SILO Stock?
What is Silo Pharma Inc (SILO)'s revenue for the last quarter?
What is Silo Pharma Inc (SILO)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Silo Pharma Inc (SILO)'s fundamentals?
How many employees does Silo Pharma Inc (SILO). have?